Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B
BACKGROUND/AIMS: Serum fibrosis scores comprised of common laboratory tests have high utility to assess severity of liver fibrosis. We aimed to derive and validate a hepatocellular carcinoma (HCC) risk score based on serum fibrosis scores to predict HCC in treatment-naïve chronic hepatitis B (CHB) patients.
METHODS: Fifteen thousand one hundred eighty-seven treatment-naïve adult CHB patients were identified to form the training cohort in this retrospective study. Individual fibrosis score was included to construct a new HCC prediction score. The score was externally validated in an independent treatment-naïve Korean CHB cohort.
RESULTS: 180/15,187 patients (1.2%) in training cohort and 47/4,286 patients (1.1%) in validation cohort developed HCC during a mean follow-up of 52 and 50 months, respectively. The newly developed HCC risk score, Liang score, is composed of gender, age, hepatitis B virus DNA, fibrosis-4 (FIB-4) index, and ranges from 0 to 22. Area under the time-dependent receiver operating characteristic curve of Liang score was 0.79 (95% confidence interval, 0.70-0.89). A cutoff value of nine provided an extremely high negative predictive value of 99.9% and high sensitivity of 90.0% at 5 years in the validation cohort. Patients with Liang score ≤9 had HCC incidence <0.2% per year in both training and validation cohorts, in whom HCC surveillance might be exempted.
CONCLUSION: A novel HCC risk score, Liang score, based on FIB-4 index, is applicable and accurate to identify treatment-naïve CHB patients with very low risk of HCC to be exempted from HCC surveillance.
| Errataetall: |
CommentIn: Clin Mol Hepatol. 2021 Jul;27(3):448-450. - PMID 34157831 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Clinical and molecular hepatology - 27(2021), 3 vom: 25. Juli, Seite 499-509 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liang, Lilian Yan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 24.09.2021 Date Revised 24.09.2021 published: Print-Electronic CommentIn: Clin Mol Hepatol. 2021 Jul;27(3):448-450. - PMID 34157831 Citation Status MEDLINE |
|---|
| doi: |
10.3350/cmh.2020.0333 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321901185 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321901185 | ||
| 003 | DE-627 | ||
| 005 | 20231225180857.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3350/cmh.2020.0333 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1072.xml |
| 035 | |a (DE-627)NLM321901185 | ||
| 035 | |a (NLM)33631920 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liang, Lilian Yan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.09.2021 | ||
| 500 | |a Date Revised 24.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Clin Mol Hepatol. 2021 Jul;27(3):448-450. - PMID 34157831 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND/AIMS: Serum fibrosis scores comprised of common laboratory tests have high utility to assess severity of liver fibrosis. We aimed to derive and validate a hepatocellular carcinoma (HCC) risk score based on serum fibrosis scores to predict HCC in treatment-naïve chronic hepatitis B (CHB) patients | ||
| 520 | |a METHODS: Fifteen thousand one hundred eighty-seven treatment-naïve adult CHB patients were identified to form the training cohort in this retrospective study. Individual fibrosis score was included to construct a new HCC prediction score. The score was externally validated in an independent treatment-naïve Korean CHB cohort | ||
| 520 | |a RESULTS: 180/15,187 patients (1.2%) in training cohort and 47/4,286 patients (1.1%) in validation cohort developed HCC during a mean follow-up of 52 and 50 months, respectively. The newly developed HCC risk score, Liang score, is composed of gender, age, hepatitis B virus DNA, fibrosis-4 (FIB-4) index, and ranges from 0 to 22. Area under the time-dependent receiver operating characteristic curve of Liang score was 0.79 (95% confidence interval, 0.70-0.89). A cutoff value of nine provided an extremely high negative predictive value of 99.9% and high sensitivity of 90.0% at 5 years in the validation cohort. Patients with Liang score ≤9 had HCC incidence <0.2% per year in both training and validation cohorts, in whom HCC surveillance might be exempted | ||
| 520 | |a CONCLUSION: A novel HCC risk score, Liang score, based on FIB-4 index, is applicable and accurate to identify treatment-naïve CHB patients with very low risk of HCC to be exempted from HCC surveillance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Carcinoma, Hepatocellular | |
| 650 | 4 | |a Fibrosis | |
| 650 | 4 | |a Hepatitis B, Chronic | |
| 650 | 4 | |a Surveillance | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Lee, Hye Won |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Vincent Wai-Sun |e verfasserin |4 aut | |
| 700 | 1 | |a Yip, Terry Cheuk-Fung |e verfasserin |4 aut | |
| 700 | 1 | |a Tse, Yee-Kit |e verfasserin |4 aut | |
| 700 | 1 | |a Hui, Vicki Wing-Ki |e verfasserin |4 aut | |
| 700 | 1 | |a Lui, Grace Chung-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Henry Lik-Yuen |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Grace Lai-Hung |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and molecular hepatology |d 2012 |g 27(2021), 3 vom: 25. Juli, Seite 499-509 |w (DE-627)NLM220236712 |x 2287-285X |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:3 |g day:25 |g month:07 |g pages:499-509 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3350/cmh.2020.0333 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 3 |b 25 |c 07 |h 499-509 | ||